Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Hims & Hers Health Stock (HIMS) Opinions on technical resistance levels

None

Resistance Levels: Social media observers are closely tracking HIMS share price action, noting a significant resistance threshold that could unlock further upside if cleared decisively.

Momentum Views: Discussion centers on the stock's potential to advance toward higher marks once that barrier falls, with participants describing an optimistic outlook on sustained movement above key benchmarks.

Portfolio Context: Some investors reference HIMS holdings alongside other growth names, comparing the fervor around its trajectory to patterns seen in other high-profile equities.

Note: This discussion summary was generated from an AI condensation of post data.

Hims & Hers Health Insider Trading Activity

HIMS Insider Trades

Hims & Hers Health insiders have traded $HIMS stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.

Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:

  • OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 10 sales selling 142,203 shares for an estimated $4,077,695.
  • MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 111,039 shares for an estimated $2,906,827.
  • DAVID B WELLS purchased 48,400 shares for an estimated $1,172,974
  • SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 3 sales selling 18,926 shares for an estimated $473,439.
  • IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 13,940 shares for an estimated $445,278.
  • PATRICK HARRISON CARROLL (Chief Medical Officer) sold 10,021 shares for an estimated $367,870
  • DEBORAH M. AUTOR (Chief Policy Officer) sold 7,054 shares for an estimated $258,952
  • GARCIA ANDREA G PEREZ sold 2,500 shares for an estimated $97,925

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

Hims & Hers Health Revenue

HIMS Quarterly Revenue

Hims & Hers Health had revenues of $608.1M in Q1 2026. This is an increase of 3.77% from the same period in the prior year.

You can track HIMS financials on Quiver Quantitative's HIMS stock page.

You can access data on HIMS stock through the Quiver Quantitative API.

Hims & Hers Health Hedge Fund Activity

We have seen 228 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 372 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Hims & Hers Health Price Targets

Multiple analysts have issued price targets for $HIMS recently. We have seen 12 analysts offer price targets for $HIMS in the last 6 months, with a median target of $26.5.

Here are some recent targets:

  • Allen Lutz from B of A Securities set a target price of $25.0 on 05/26/2026
  • Jailendra Singh from Truist Securities set a target price of $23.0 on 05/22/2026
  • Ryan MacDonald from Needham set a target price of $35.0 on 05/12/2026
  • Cory Carpenter from JP Morgan set a target price of $33.0 on 05/12/2026
  • Daniel Grosslight from Citigroup set a target price of $28.0 on 05/12/2026
  • Jonna Kim from TD Cowen set a target price of $23.0 on 03/27/2026
  • Michael Cherny from Leerink Partners set a target price of $25.0 on 03/16/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles